Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today

Core Insights - Nektar Therapeutics reported positive results from a phase 2b study of rezpegaldesleukin, leading to a stock price increase of over 15%, significantly outperforming the S&P 500 index's 0.5% gain [1] Group 1: Clinical Trial Results - The phase 2b study focused on rezpegaldesleukin for treating moderate to severe atopic dermatitis, showing statistical significance in improving the eczema area and severity index compared to a placebo over 16 weeks [2][3] - Key secondary endpoints also indicated a reduction in the severity of the disorder, with participants experiencing more profound effects when continuing treatment [4] Group 2: Drug Development and Future Prospects - Rezpegaldesleukin is also being developed for severe alopecia areata, with the next clinical testing readout expected in December [4] - The company's chief research and development officer highlighted the potential of Tregs (regulatory T-cells) as a new therapeutic approach for inflammatory skin disorders [5]